Methods for the preparation of polymeric films which encase and preserve bioactive agents. In particular, the invention is directed to the preparation of oral thin films containing bioactive proteins or viruses. For example, methods and compositions are disclosed for preservation of rotavirus and antibodies in thin dry films.

This invention relates to the delivery of heterologous peptides or proteins such as therapeutic peptides, therapeutic proteins or antigens to mucosal sites using vesicles derived from the outer membrane of commensal bacteria, recombinant bacteria capable of producing such vesicles, and methods for the production of such vesicles. The invention further relates to an inducible expression system for use in recombinant bacteria.

Provided herein are engineered Salmonella enterica serovar Typhimurium strains and compositions, including vaccines, thereof. Also provided herein are methods of treating and/or preventing infection by at least Salmonella enterica serovar Typhimurium in a subject in need thereof by administering a vaccine provided herein.

Described herein are compositions and methods for making and using recombinant bacteria that are capable of regulated attenuation and/or regulated expression of one or more antigens of interest.

The present disclosure relates to nanoparticle compositions for use as vaccines against Salmonella.

The present disclosure relates to nanoparticle compositions for use as vaccines against Clostridium perfringens in poultry which causes necrotic enteritis in poultry. Such compositions include one or more Clostridium perfringens extracellular proteins entrapped in a polyanhydride or chitosan nanoparticle. The one or more Clostridium perfringens extracellular proteins may include one or more Clostridium perfringens toxins, such as, for example, alpha toxin (CPA), beta toxin (CPB), epsilon toxin (ETX), iota toxin (ITX), perfringolysin O (PFO), enterotoxin (CPE), beta2 toxin (CPB2), or NetB toxin. In some aspects, the composition further includes a Salmonella enteritidis flagellar protein. The present invention also includes methods for the oral delivery of one or more Clostridium perfringens extracellular proteins to the mucosal membrane of the intestinal tract of a bird of the order Galliformes.

Compositions capable of enhancing and/or eliciting an immune response in a subject and methods of using the compositions. The compositions are capable of enhancing an IgA immune response and/or an IgG immune response and comprise an agent capable of reducing the level of binding of ATP to a P2X7 receptor to a subject. The compositions are for oral administration.

The present invention is directed to methods and agents used for treating cancer in Toll-Like Receptor 5-expressing tissues by providing a Toll-Like Receptor agonist such as flagellin. The present invention also relates to protecting the liver from a liver toxicity using a Toll-like receptor agonist.

Provided herein are compositions comprising substantially non-viable Gram-negative bacterial organisms that have a substantial reduction in endotoxin activity and/or pyrogenicity and methods for treating a cancer using the same. Also provided are methods for treating cancer provided herein, comprising administering to a mammal diagnosed with cancer, substantially non-viable Gram-negative bacteria having a substantial reduction in endotoxin activity and/or pyrogenicity, in an amount sufficient to inhibit growth or metastasis of the cancer. An additional method is provided comprising administering viable or non-viable Gram-negative bacterial organisms that have a genetic defect that results in a substantial loss of lipopolysaccharide within the outer membrane of the bacteria. Further provided are methods for reducing endotoxin activity and/or pyrogenicity in Gram-negative bacteria comprising treatment with polymyxin and glutaraldehyde.

Described herein are compositions and methods for making and using recombinant bacteria that are capable of regulated attenuation, regulated expression of one or more antigens of interest, and/or N-glycan modification of secreted/surface antigens.